Key Details
Price
$18.75Last Dividend
$0.25Annual ROE
28.97%Beta
0.51Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Sept 08, 2015Next split:
N/ARecent split:
June 03, 2014Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Zai Lab Limited and Innoviva Specialty Therapeutics have received approval from China's NMPA for Zai Lab's NDA for XACDURO® (sulbactam-durlobactam) for the treatment of HABP/VABP caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus comp.
Innoviva, Inc. is a biopharma company focused on the development and commercialization of pharmaceutical products. However, the company's main asset is royalty revenues that come from products it receives from Glaxo Group Limited. There has been a lot of movement at the company over the past 12-18 months on myriad fronts.
The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FAQ
- What is the primary business of Innoviva?
- What is the ticker symbol for Innoviva?
- Does Innoviva pay dividends?
- What sector is Innoviva in?
- What industry is Innoviva in?
- What country is Innoviva based in?
- When did Innoviva go public?
- Is Innoviva in the S&P 500?
- Is Innoviva in the NASDAQ 100?
- Is Innoviva in the Dow Jones?
- When was Innoviva's last earnings report?
- When does Innoviva report earnings?
- Should I buy Innoviva stock now?